Email Updates

You are here

Long-Acting Injectable Cabotegravir

Long-acting injectable PrEP is an experimental strategy based on the drug cabotegravir, an antiviral medication.

Two studies, HPTN 083 and HPTN 084, have shown high levels of protection using cabotegravir as a long acting injectable (CAB-LA). HPTN 083 gathered data among men who have sex with men, transgender women. HPTN 084 investigated the same product among cisgender women.

In December of 2021, the FDA approved CAB-LA as PrEP, making it the first injectable PrEP to be added to the toolbox of proven prevention methods, along with male and female condoms, daily oral PrEP, voluntary medical male circumcision and the Dapivirine Vaginal Ring.

Scroll down for resources on CAB-LA research and advocacy.

Updates

Understanding the Research Results

Putting the Research in Context